Custom-Made mRNA Cancer Vaccine Clears Its Toughest Hurdle in Landmark Melanoma Trial

Merck and Moderna have delivered the first-ever positive Phase III results for a personalized mRNA cancer vaccine — a watershed moment that could redefine how we fight tumors. In the INTerpath-001 trial, enrolling 1,137 patients with completely resected stage IIB-IV melanoma, the combination of intismeran autogene plus Merck's blockbuster immunotherapy Keytruda beat Keytruda alone on both the primary endpoint of recurrence-free survival and the key secondary...